MedTrace Logo

A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis

NCT05014360 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2023-06-02

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of JNJ-64251330 in participants with Familial Adenomatous Polyposis (FAP) on colorectal polyp burden (sum of the polyp diameters).

Conditions

  • Adenomatous Polyposis Coli

Interventions

DRUG

JNJ-64251330

JNJ-64251330 tablets will be administered orally.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-10
Primary Completion
2023-02-15
Completion
2023-02-15
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Netherlands
  • Puerto Rico
  • South Korea
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05014360 on ClinicalTrials.gov